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Abstract
Little is known about the mechanisms leading to neurodegeneration in multiple sclerosis (MS) and the role of peripheral blood
cells in this neurodegenerative component. We aimed to correlate brain radiological phenotypes deﬁned by high and low
neurodegeneration with gene expression proﬁling of peripheral blood mononuclear cells (PBMC) from MS patients. Magnetic
resonance imaging (MRI) scans from 64 patients with relapsing-remitting MS (RRMS) were classiﬁed into radiological
phenotypes characterized by low (N = 27) and high (N = 37) neurodegeneration according to the number of contrast-enhancing
lesions, the relative volume of non-enhancing black holes on T1-weighted images, and the brain parenchymal fraction. Gene
expressionproﬁlingwas determined in PBMCusingmicroarrays, and validation of selected geneswas performed by polymerase
chain reaction (PCR). B-cell immunophenotyping was conducted by ﬂow cytometry. Microarray analysis revealed the B-cell
speciﬁc genes FCRL1, FCRL2, FCRL5 (Fc receptor-like 1, 2 and 5 respectively), and CD22 as the top differentially expressed genes
between patientswith high and lowneurodegeneration. Levels for these geneswere signiﬁcantly down-regulated in PBMC from
patients with MRI phenotypes characterized by high neurodegeneration and microarray ﬁndings were validated by PCR. In
patients with high neurodegeneration, immunophenotyping showed a signiﬁcant increase in the expression of the B-cell
activation markers CD80 in naïve B cells (CD45+/CD19+/CD27−/IgD+), unswitched memory B cells (CD45+/CD19+/CD27+/IgD+),
and switched memory B cells (CD45+/CD19+/CD27+/IgD−), and CD86 in naïve and switched memory B cells. These results
suggest that RRMS patients with radiological phenotypes showing high neurodegeneration have changes in B cells
characterized by down-regulation of B-cell-speciﬁc genes and increased activation status.
Introduction
Multiple sclerosis (MS) pathogenesis is characterized by at least
two major processes, inﬂammation and neurodegeneration (1).
Whereas inﬂammation predominates in the initial phases of
the disease, the neurodegenerative component is usually more
prominent in the late stages of MS, although it can be present
early in the disease course (2). Current available therapies in
MS have proven to be highly effective to suppress the inﬂamma-
tory component of the disease. In contrast, the mechanisms
leading to neurodegeneration are less well understood and,
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unfortunately, existing therapies remain largely ineffective in pa-
tients where the neurodegenerative component dominates (3,4).
In this context, a better understanding of the mechanisms of
neurodegeneration occurring inMSmay help to identify molecu-
lar targets that set the rationale for the design of speciﬁc and ef-
fective therapeutic approaches to prevent neurodegeneration.
A large number of gene expression proﬁling studies using
DNA microarrays have been conducted in peripheral blood
cells from MS patients pursuing the identiﬁcation of speciﬁc
blood transcriptomic patterns that may help to differentiate MS
patients from healthy individuals or patients with other auto-
immune conditions, or between MS patients with different
clinical forms and activity phases of the disease (5). In the present
study, we aimed to gain more insight into the mechanisms of
neurodegeneration operating in MS by correlating gene expres-
sion microarray ﬁndings in peripheral blood mononuclear cells
(PBMC) from MS patients with magnetic resonance imaging
(MRI) phenotypes characterized by high and low neurodegenera-
tive components.
Results
B-cell speciﬁc genes are differentially expressed between
patients with high and low neurodegeneration
Gene expression proﬁling was ﬁrst determined in PBMC isolated
from relapsing-remitting MS (RRMS) patients with MRI pheno-
types characterized by high and low neurodegenerative compo-
nents, as described in Materials and Methods. Analysis of
microarray data revealed B-cell speciﬁc genes among the top
differentially expressed genes between patients with high and
low neurodegeneration: FCRL1, FCRL2, FCRL5 (Fc receptor-like 1,
2 and 5 respectively), and CD22 (Table 1). The full list of additional
differentially expressed genes with P-values <0.01 is provided as
Supplementary Material, Table S1.
As shown in Fig. 1A, mRNA expression Q2levels for these genes
were signiﬁcantly lower in PBMC from patients with MRI pheno-
types characterized by a high neurodegenerative component
comparedwith PBMC frompatients with lowneurodegeneration.
PCR validation of FCRL1, FCRL2, FCRL5, CD22 as down-
regulated genes in patients with high neurodegeneration
We next approached the validation of differentially expressed
B-cell speciﬁc genes obtained with microarrays by means of
real-time PCR relative quantiﬁcation in a subgroup of RRMS
patients. As depicted in Figure 1B, microarray ﬁndings for
FCRL1, FCRL2, FCRL5, CD22 were validated by PCR and mRNA ex-
pression levels for these geneswere signiﬁcantly down-regulated
in PBMC from patients with high neurodegeneration compared
with patients with low neurodegeneration.
B cells are more activated and express more IL-6 in RRMS
patients with high neurodegeneration
Considering the immunomodulatory B-cell-related role of FCRL1,
FCRL2, FCRL5 and CD22, and their preferential expression in
B cells (Supplementary Material, Fig. S1), we next aimed to inves-
tigate the activation status of B cells fromRRMSpatientswithMRI
phenotypes characterized by high neurodegeneration. To rule
Table 1. Top differentially expressed genes obtained with microarrays in PBMC from RRMS patients with high and low neurodegenerative
components in brain MRI
Affymetrix probe set Symbol Description LogFC P value
221239_s_at FCRL2 Fc receptor-like 2 −1.083 5.3 × 10−5
1563674_at FCRL2 Fc receptor-like 2 −1.069 5.0 × 10−4
243968_x_at FCRL1 Fc receptor-like 1 −1.063 5.6 × 10−4
204287_at SYNGR1 Synaptogyrin 1 1.027 6.6 × 10−4
224558_s_at MALAT1 Metastasis associated lung adenocarcinoma transcript 1 (non-protein coding) −1.049 8.1 × 10−4
223176_at KCTD20 Potassium channel tetramerisation domain containing 20 1.029 8.8 × 10−4
235982_at FCRL1 Fc receptor-like 1 −1.083 9.3 × 10−4
241401_at C4orf12 Chromosome 4 open reading frame 12 1.045 1.2 × 10−3
240261_at TOM1L1 Target of myb1 (chicken)-like 1 −1.037 1.3 × 10−3
38521_at CD22 CD22 molecule −1.037 1.4 × 10−3
204581_at CD22 CD22 molecule −1.048 1.5 × 10−3
207819_s_at ABCB4 ATP-binding cassette, sub-family B (MDR/TAP), member 4 −1.062 2.1 × 10−3
210538_s_a BIRC3 Baculoviral IAP repeat-containing 3 −1.038 2.1 × 10−3
217512_at KNG1 Kininogen 1 1.041 2.4 × 10−3
Affymetrix probe set Symbol Description LogFC P value
202732_at PKIG Protein kinase (cAMP-dependent, catalytic) inhibitor gamma −1.043 2.5 × 10−3
1559059_s_at ZNF611 Zinc ﬁnger protein 611 1.034 2.6 × 10−3
1560683_at BCL8 B-cell CLL/lymphoma 8 −1.039 2.8 × 10−3
228485_s_at SLC44A1 Solute carrier family 44, member 1 1.048 3.0 × 10−3
212423_at ZCCHC24 Zinc ﬁnger, CCHC domain containing 24 1.030 3.0 × 10−3
1568706_s_at AVIL Advillin −1.041 3.1 × 10−3
230718_at HSF5 Heat shock transcription factor family member 5 −1.055 3.1 × 10−3
224404_s_at FCRL5 Fc receptor-like 5 −1.087 3.2 × 10−3
238417_at PGM2L1 phosphoglucomutase 2-like 1 −1.025 3.2 × 10−3
204004_at PAWR PRKC, apoptosis, WT1, regulator −1.056 3.3 × 10−3
224406_s_at FCRL5 Fc receptor-like 5 −1.058 3.5 × 10−3
Analysis was adjusted by age. B-cell speciﬁc genes are shown in bold. LogFC: mean log fold change, and positive/negative values indicate higher/lower gene expression
levels in PBMC from patients with high neurodegenerative component versus patients with low neurodegenerative component respectively. None of the P values was
<0.05 after correction for multiple testing.
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out that the transcriptional differences observed for B-cell specif-
ic genes were not due to differences in the number of B cells, we
analyzed the relative percentage of B cells in patients with high
and low neurodegeneration. As shown in Figure 2A, the percent-
age of CD19+ B cells in PBMC was comparable between both
groups of patients (P = 0.472). Immunophenotyping of the B-cell
population revealed a trend towards increased expression of
the B-cell activation marker CD80 in CD19+ B cells from
patients with high neurodegeneration (P = 0.05; Fig. 2B). Further
B-cell-speciﬁc immunophenotyping showed a signiﬁcant in-
crease in the expression of CD80 in naïve B cells (P = 0.04), un-
switched memory B cells (P = 0.03), and switched memory
B cells (P = 0.008) in PBMC from patients with MRI phenotypes
characterized by high neurodegeneration compared with
patients with low neurodegeneration phenotypes (Fig. 2B).
Expression of the B-cell activation marker CD86 was also found
signiﬁcantly increased in naïve B cells and switched memory
B cells (P = 0.04 and P = 0.02 respectively; Fig. 2C) from patients
with high neurodegeneration.
Immunophenotyping of the B-cell speciﬁcmarkers FCRL1, FCRL2
and CD22 did not reveal statistically signiﬁcant differences between
patients with high and low neurodegeneration for any of the B-cell
populations analyzed (Supplementary Material, Table S2 shows the
full list of variables included in the immunophenotyping).
Finally, intracellular cytokine determination by CD19+ B cells
revealed a signiﬁcantly higher expression of IL-6 by B cells from
patients with high neurodegeneration compared with patients
with low neurodegeneration (P = 0.03; Fig. 2D). No signiﬁcant dif-
ferences (P < 0.05) were observed between both groups of patients
for TNF [mean percentage of CD19+ B cells expressing TNF
(standard deviation): 21.9 (7.8) for patients with low neurodegen-
eration; 31.0 (19.3) for patients with high neurodegeneration] and
IL-10 [mean percentage of CD19+ B cells expressing IL-10 (stand-
ard deviation): 1.0 (0.7) for patients with low neurodegeneration;
2.5 (2.1) for patients with high neurodegeneration].
Discussion
Little is known about the neurodegenerative mechanisms operat-
ing inMSpatients. In an attempt to investigate a potential involve-
ment of peripheral blood immune cells in the neurodegenerative
component of the disease, brain MRI scans from RRMS patients
were classiﬁed into radiological phenotypes characterized by
high and lowneurodegeneration and correlatedwith differentially
Figure 1.mRNA expression levels of differentially expressed B-cell speciﬁc genes in patients with high and low neurodegeneration. (A) Expression levels of FCRL1, FCRL2,
FCRL5, CD22 obtainedwithmicroarrays. Three samples from the low neurodegeneration groupwere not included formicroarray analysis due to poor total RNA quality. (B)
Validation of FCRL1, FCRL2, FCRL5, CD22 by means of real-time PCR. Results are expressed as fold change in gene expression in PBMC from RRMS patients with high
neurodegeneration relative to patients with low neurodegeneration.
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expressed genes observed in PBMC form patients using microar-
rays. Gene expression analysis pointed to the B-cell speciﬁc
genes FCRL1, FCRL2, FCRL5 and CD22 as the top differentially ex-
pressed genes between MS patients with divergent radiological
phenotypes, with lower expression in those patients whose
brain MRI scans showed high neurodegeneration.
FCRL genes encode cell-surface membrane proteins preferen-
tially expressed on B-lineage cells and containing both immunor-
eceptor tyrosine-based activation and inhibitory motifs (ITAM
and ITIM, respectively) (6). The potential of FCRL molecules to
deliver activating and/or inhibitory signals suggests that these
receptors could inﬂuence B-cell signaling and hence play immu-
nomodulatory roles in these cells (6). CD22 codes for amembrane
glycoprotein expressed on B cells, which also contains ITIMs and
functions as a co-receptor of the B-cell receptor (7). Interestingly,
inhibitory roles in B-cell activation have been described for FCRL2
(8), FCRL5 (9) and CD22 (10). In our study, peripheral blood B cells
were more activated in patients with high neurodegeneration, as
revealed by the higher expression of CD80 in all B-cell subsets im-
munophenotyped, and CD86 in some B-cell populations. In add-
ition, expression of the pro-inﬂammatory cytokine IL-6 was
increased in B cells from patients with neurodegeneration.
It is generally accepted that B cells may contribute to the
pathogenesis of MS in different ways: B cells differentiate to plas-
ma cells which possibly secrete pathogenic antibodies that target
oligodendrocytes and participate in the demyelination process
(11); they may function as efﬁcient antigen-presenting cells for
the activation of T cells (12); and B cells may regulate inﬂamma-
tory processes via secretion of pro-inﬂammatory (IL-6, TNF) and
anti-inﬂammatory (IL-10) cytokines (12). The potential role of B
cells in the neurodegenerative component of MS and disease
progression is less understood. It is relevant to mention that
together with T cells, B cells are abundant in subpial cortical
lesions associated with plaque-like primary demyelination and
neurodegeneration, a ﬁnding that is speciﬁc for MS and not
observed in other inﬂammatory and non-inﬂammatory neuro-
logical conditions disorders (13). Furthermore, B-cell-enriched
follicle-like aggregates have been reported in the meninges of
patients with chronic progressive disease course and associated
with large subpial cortical lesions, microglia activation and
neuronal loss (14).
Our study associates changes at the transcriptional level
in PBMC from MS patients with radiological phenotypes show-
ing high neurodegeneration. The nature of top differentially
Figure 1. Continued
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Figure 2. B-cell immunophenotyping in patients with high and low neurodegeneration. (A) Relative percentage of CD19+ B cells in PBMC. (B) Expression of the B-cell
activation marker CD80 in the whole CD19+ B-cell population and in the different B-cell subpopulations. (C) Expression of the B-cell activation marker CD86 in naïve
and switched memory B cells. (D) Percentage of CD19+ B cells expressing IL-6. Naïve B cells were considered as CD45+/CD19+/CD27−/IgD+. Unswitched memory B cells
were considered as CD45+/CD19+/CD27+/IgD+. Switchedmemory B cells were considered as CD45+/CD19+/CD27+/IgD−. Analysis of ﬂow cytometry immunophenotyping
was adjusted by age. MFI, mean ﬂuorescence intensity (median values). Low, patients with low neurodegeneration (N = 17 for A–C; N = 5 for D). High, patients with high
neurodegeneration (N = 18 for A–C; N = 6 for D).
Human Molecular Genetics | 5
515
520
525
530
535
540
545
550
555
560
565
570
575
580
585
590
595
600
605
610
615
620
625
630
635
640
expressed genes and immunophenotyping point to B cells as the
peripheral blood cell population altered in patients with high
neurodegeneration. These ﬁndings are descriptive and only sug-
gest an involvement of B cells in the neurodegenerative compo-
nent of MS. How these B cell changes may translate into higher
degrees of brain atrophy and tissue destruction is unknown
and not addressed in the study. However, the positive effects of
the B-cell depleting agent ocrelizumab in a recent Phase III clin-
ical trial in patients with progressive disease (ORATORIO;
NCT01194570) on the primary endpoint, conﬁrmed disability pro-
gression sustained for ≥12 weeks, supports a role of B cells in the
neurodegenerative component of the disease (unpublished data).
In our study, it is important to comment that ﬁndings in gene
expression and immunophenotyping were not due to age differ-
ences between patients with high and low neurodegeneration,
insomuch as statistical analysis was considering this covariate.
Similarly, down-regulation of B cell genes was not secondary to
a lower representation of B cells in patients with high neurode-
generation, since the percentage of CD19+ B cells in PBMC did
not differ between both groups of patients. We failed to demon-
strate a lower protein expression of FCRL1, FCRL2 and CD22 in the
different B-cell subsets by ﬂow cytometry in patients with high
neurodegeneration, although factors such as lower sample size
and differences in the sensitivities of the techniques used to
measure the molecules (PCR versus ﬂow cytometry) may well
explain the negative ﬁndings.
In summary, the aggregate ﬁndings of the study suggest that
RRMSpatientswhose brainMRI scans showhigh neurodegenera-
tion have associated changes in the population of peripheral
blood B cells characterized by down-regulation of B-cell-speciﬁc
genes and higher activation status.
Materials and Methods
MRI analyses and patients
MRI of the brain was acquired on a 1.5 T superconductivemagnet
using a standardized protocol (2D fast spin-echo T2-weighted,
and pre- and post-contrast (0.1 mmol/kg, 5 min delay) 2D spin-
echo T1-weighted sequences). For all sequences 46 interleaved
contiguous axial sections were acquired with a 3-mm section
thickness covering the whole brain, with an in-plane spatial
resolution of ∼1 × 1 mm.
In all patients, two experienced neuroradiologists visually as-
sessed the presence and number of gadolinium (Gd) enhancing
lesions on post-contrast T1-weighted scans. Brain parenchymal
fraction (BPF), a normalized brain volume measure, commonly
used as a surrogate of whole-brain atrophy, was calculated on
the pre-contrast T1-weighted scans using a fully automated seg-
mentation technique as previously described (15).
For calculating the non-enhanced T1 black hole volume we
used an in-house automatic segmentation algorithm that meas-
ure the T1-lesion load from the initial T2-lesion segmentation
that was used as lesion mask. T2 lesion segmentation was
performed using a semiautomatic local thresholding contour
technique (Dispimage, DL Plummer, University College, London,
UK) or in case the lesion could not be outlined satisfactorily with
this approach, by manual outlining. Relative T1 black hole vol-
ume or black hole fraction (BHf) is expressed as the ratio of T1 le-
sion volume to the T2 lesion volume.
Due to the design of the present study, in which we used pre-
viously acquired MRI data, we could not use high resolution 3D
T1-weigted images, which are probably the optimal sequence
for calculating regional brain volumes due to the high contrast
they provide between grey and white matter. However, the 2D
sequencewe used in this study, which is the standard of practice
in many institutions, at least when 1.5 T magnets are used, is
adequate for calculating global brain volume, and has been com-
monly used for that purpose inmany clinical studies and clinical
trials (16,17).
Figure 3 illustrates the MRI-based stratiﬁcation algorithm ap-
plied to the study [modiﬁed from Bielekova et al. (18)]. In order to
identify peripheral blood gene expression patterns associated
with radiological phenotypes characterized by high tissue de-
struction andminimize the effect of inﬂammation on the neuro-
degenerative component, MRI scans were ﬁrst classiﬁed into low
inﬂammation and high inﬂammation phenotypes according to
the number of contrast-enhancing lesions. Subsequent MRI ana-
lyses were performed on low inﬂammation radiological pheno-
types which were deﬁned by the presence of ≤1 Gd-enhancing
lesions. MRI phenotypes with high neurodegenerative compo-
nent were deﬁned as follows: (i) the presence of BPF values
<0.83; or (ii) BPF values ≥0.83 and presence of BHf values ≥10%.
MRI phenotypes with low neurodegenerative component were
deﬁned by the presence of BPF values ≥0.83 and BHf values
<10%. These cut-off values were selected, to separate the groups,
based on a previous study that used similar techniques and
T1-weighted sequences for calculating them (18).
The initial cohort comprised 108 RRMS patients with MRI ex-
aminations performed as part of a prospective study of patients
receiving treatment with interferon-beta (IFNβ). MRI scans corre-
sponded to the baseline determination before IFNβ and none of
the patients had ever received treatment with immunomodula-
tors or immunosuppressants before study entry. Sixty-four out
of 108 RRMSpatients hadMRIphenotypes characterized by low in-
ﬂammation and were included in the study. Of these, 27 patients
had low and 37 patients high neurodegeneration phenotypes.
Table 2 shows a summary of demographic and clinical character-
istics of RRMS patients. Mean age of Q3patients with high neurode-
generation phenotypes was signiﬁcantly higher compared with
patients with low neurodegeneration phenotypes.
The study was approved by the Hospital ethics committee,
and all patients gave their informed consent.
Sample collection and gene expression microarrays
Peripheral blood was extracted in proximity to the MRI scans
[mean days (standard deviation): 49.3 days (47.3) for patients
with low neurodegeneration; 52.2 days (41.8) for patients with
high neurodegeneration]. None of the patients received cortico-
steroid treatment within 1 month before MRI scans and blood
collection. PBMC from patients were isolated by Ficoll-Isopaque
density gradient centrifugation (Gibco BRL, Life Technologies
LTD, UK) and stored in liquid nitrogen until used. Total RNA
was extracted from PBMC using an RNeasy kit (Quiagen, Santa
Clarita, USA) and hybridized to microarray expression chips
(Affymetrix Human Genome U133A Plus 2.0 arrays) according
to the manufacturer´s protocol (Affymetrix Inc., Santa Clara, CA,
USA).
Statistical analysis of microarray data
Analysis of the expression data was carried out by using the
Bioconductor packages for the R programming environment.
All chips were explored one by one and checked for quality. Sub-
sequently, data obtained from .CEL ﬁles were preprocessed using
the RMA method (19) implemented in Affymetrix Expression
Console software. Linear models for microarray data R package
6 | Human Molecular Genetics
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(20) were used to identify differentially expressed genes between
RRMS patients with high and lowneurodegenerationMRI pheno-
types. Considering the statistically signiﬁcant differences in age
between both groups of patients, expression values for analysis
were adjusted by age.
Validation of microarray data with real-time PCR
Expression levels of selected geneswere determined by real-time
quantitative reverse transcription PCR in a subgroup of 23 pa-
tients with high and 22 patients with low neurodegeneration phe-
notypes. As shown in Supplementary Material, Table S3, this
subgroup of patients was representative of the original cohort
used for gene expression proﬁling. Total RNA was obtained from
the same samples that had been used for the microarrays. cDNA
was synthesized from total RNA using the High Capacity cDNA Re-
verse Transcription (Applied Biosystems, Foster City, CA, USA). Am-
pliﬁcations were performed in duplicate using Taqman probes
speciﬁc for FCRL1, FCRL2, FCRL5 (Fc receptor-like 1, 2 and 5 respect-
ively) and CD22 (Applied Biosystems). The housekeeping gene
GAPDH was used as an endogenous control. The threshold cycle
(CT) value foreach reaction, and the relative level of gene expression
for each sample were calculated using the 2−ΔΔCT method (21).
B-cell ﬂow cytometry immunophenotyping and B-cell
subpopulations
Immunophenotyping of B cells was performed in frozen PBMC
from a subgroup of 18 patients with high and 17 patients with
low neurodegeneration phenotypes. This cohort was representa-
tive of the original cohort used for microarray studies (Supple-
mentary Material, Table S3). For B-cell surface marker staining
PBMC were thawed at 37°C, blocked with human IgG for 20 min
at room temperature, and labeled with optimal concentrations
of anti-CD45-APC-Cy7, anti-CD19-PerCP-Cy5.5, anti-IgD-FITC,
anti-CD27-APC, anti-FCRL1-PE, anti-FCRL2-PE, anti-CD22-PE, or
the corresponding isotype controls for 30 min at room tempera-
ture. For B-cell activation assessment, PBMC were thawed at 37°
C and labeled with optimal concentrations of anti-CD45-APC-
Cy7, anti-CD19-PerCP-Cy5.5, anti-IgD-FITC, anti-CD27-APC,
anti-CD80, anti-CD86 or the isotype controls for 30 min at room
temperature. Samples were analyzed on a standard FACSCanto
I instrument (Becton Dickinson, BD, New Jersey, USA). Analysis
was performed using the BD FACSDiva software v.5.3. At least
20 000 lymphocyte-gated cells were analyzed for each sample.
B cells were classiﬁed into different subtypes according to the
expression of their surface markers: (i) naïve B cells (CD45+/CD19
+/CD27−/IgD+); (ii)memory B cells (CD45+/CD19+/CD27+); (iii) un-
switched memory B cells (CD45+/CD19+/CD27+/IgD+); and (iv)
switched memory B cells (CD45+/CD19+/CD27+/IgD−). FCRL1,
FCRL2, CD22, CD80 and CD86 expression was evaluated in the
abovementioned B-cell subpopulations. B-cell activation was in-
vestigated by examining CD80 and CD86 expression in the differ-
ent B-cell subpopulations.
Regarding the statistical analysis of ﬂow cytometry data, the
observed values of cell counts and population frequencies were
adjusted by age. For each observation, the Welch’s two sample
Figure 3. Q6Stratiﬁcation algorithmapplied to brainMRI scans to identify radiological phenotypeswith high and lowneurodegeneration. To identify gene expression proﬁles
speciﬁcally associated with the neurodegeneration component and exclude the effect of inﬂammation, only RRMS patients with low inﬂammation phenotypes (≤1 Gd+
lesions) were included in the study. Further stratiﬁcation of low inﬂammation phenotypes into high and low neurodegeneration phenotypes was performed according to
the combination of BPF and BHf, as detailed in theMaterials andMethods. In patients with high and low neurodegeneration, PBMCwere isolated and the gene expression
proﬁlingwas determined from these cells bymeans ofmicrorrays. BPF, brain parenchymal fraction; BHf: black hole fraction; Gd+ lesions, numberof Gd-enhancing lesions;
PBMC, peripheral blood mononuclear cells; Y (yes), indicates that the condition is satisﬁed; N (no), indicates that the condition is not fulﬁlled.
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t-test was applied and P-values <0.05 were considered statistical-
ly signiﬁcant.
Intracellular cytokine production by B cells
Cytokineproduction byB cellswasperformed in frozenPBMC froma
representative subgroup of 11 patients, 6 with high and 5 with low
neurodegeneration phenotypes (Supplementary Material, Table S3).
PBMC were thawed and suspended in 1 ml of RPMI 1640 medium
supplemented with 10% fetal calf serum, 2 m glutamine and
20 ng/ml of gentamycin (all from Gibco BRL, Karlsruhe, Germany)
at a concentration of 106 cells/ml. To explore intracellular TNF-α
and IL-6 production by B cells two 1ml aliquots were cultured in
the presence or absence of 50 ng/ml phorbol 12-myristate 13-acetate
(PMA; Sigma-Aldrich) and 750 ng/ml ionomycin (Sigma-Aldrich).We
added 2 µg/ml brefeldin A (GolgiPlug, BD Biosciences) to both ali-
quots and incubated them with 5% CO2 at 37°C for 4 h. For testing
intracellular IL-10 production, PBMCs were cultured for 24 h with
complete medium containing 3 μg/ml CpG ODN (Invivogen). In the
last 4 h of culture we added 50 ng/ml PMA, 750 ng/ml ionomycin,
0.7 μl of GolgiStop (BD Biosciences) and 2 μg/ml brefeldin A. After in-
cubation, cells were washed with saline. PBMC were surface stained
with anti-CD3-PerCP, anti-CD19-PeCy7, anti-CD45-APC (BD Bios-
ciences) for 30 min at 4°C. For intracellular labeling, cells were
washed in PBS and resuspended in 200 μl of cytoﬁx/cytoperm (BD
Biosciences). After 20min at 4°C, cells were washed in Perm/Wash
buffer (BD Biosciences), pellets resuspended and stained intracellu-
larly with anti-TNFα-FITC (BD Biosciences), anti-IL-6-PE (BD Bios-
ciences) or anti-IL-10-PE (Biolegend) for 30min at 4°C and washed.
Finally, cells were analyzed on a standard FACSCanto II instrument
and analyzed in FACSDiva software (BD Biosciences). A minimum
of 30 000 events were collected for analysis of antigen staining.
Supplementary Material
Supplementary Material is available at HMG online.
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